Propagenix’s proprietary technologies focus on the bioproduction of tissue-specific epithelial stem cells to create novel cell therapies, diagnostics and research tools. Our lead therapeutic program is an advanced engineered skin tissue “chassis” enabling autologous treatment of multiple skin disorders. The company has generated $1.85M in non-dilutive revenue from >10 research agreements, licenses and grants and is raising an A round of $5-6M.